Answers are grounded in this paper and cite their sources.
Background Preventive therapy is a key element of migraine management, and there is limited evidence comparing monotherapy and combination regimens of established agents. Objective To compare nortriptyline monotherapy and combination therapy in the treatment of recurrent migraine of moderate frequency. Methods This was a single-center, retrospective, descriptive paper involving 252 patients diagnosed with episodic migraine. The studied patients received either nortriptyline monotherapy ( n = 45), nortriptyline/flunarizine ( n = 84), or nortriptyline/flunarizine/tizanidine ( n = 123). Results Headache frequency reduced in all therapeutic regimens ( p < 0.0001). Triple therapy (from 9.8 ± 0.5 to 2.8 ± 1.0 days/month at 4 months) showed the greatest improvement, followed by dual therapy (from 8.8 ± 1.1 to 3.7 ± 1.1). There was marginal improvement with monotherapy (from 7.8 ± 0.6 to 5.7 ± 2.2). Patients who received combination therapy had significantly higher adherence than those on monotherapy (≈75% vs 55.6%; p = 0.027). Side effects were reported in 25% of patients, mainly mild. More than 75% of patients indicated a medium-to-high level of satisfaction. Conclusions Combination therapy using nortriptyline was linked to greater decreases in the frequency of headache and enhanced adherence than monotherapy. Tolerability, as well as patient satisfaction, were satisfactory. These practical findings confirm rational polytherapy when monotherapy proves ineffective.
No takes yet. Share an insight, caveat, or question.
Krymchantowski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: